Triple meeting – targeted focus validates Merus’s change of tack
Merus’s anti-Her2/Her3 bispecific could have a future in a new targeted setting.
Corporate venture firms – dedicated followers of fashion?
Eagerly pursuing all the latest fads and trends.
